Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
The literature review discusses approaches to the treatment of patients with chronic heart failure and preserved ejection fraction (EF>50) – HFpEF. The impact of various groups of drugs on the prognosis and quality of life of patients in this cohort was assessed based on the results of random...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
2022-10-01
|
| Series: | Сеченовский вестник |
| Subjects: | |
| Online Access: | https://www.sechenovmedj.com/jour/article/view/870 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849403652955963392 |
|---|---|
| author | A. A. Kuzmenko A. A. Sokolova D. A. Napalkov |
| author_facet | A. A. Kuzmenko A. A. Sokolova D. A. Napalkov |
| author_sort | A. A. Kuzmenko |
| collection | DOAJ |
| description | The literature review discusses approaches to the treatment of patients with chronic heart failure and preserved ejection fraction (EF>50) – HFpEF. The impact of various groups of drugs on the prognosis and quality of life of patients in this cohort was assessed based on the results of randomized trials, systematic reviews and meta-analyses, clinical recommendations of recent years. To date, only sodium-glucose cotransporter-2 inhibitors unequivocally improve the quality of life and prognosis of patients with HFpEF. Angiotensin receptor – neprilysin inhibitors and mineralocorticoid receptor antagonists are effective in terms of prognosis and quality of life only in patients with HFpEF in combination with resistant hypertension. In patients with sinus rhythm, heart rate > 70 beats/min and concomitant coronary artery disease, a combination of bisoprolol and ivabradine may be considered. Diuretics are recommended for patients with HFpEF when there are signs of congestion and signs of decompensation. Other groups of drugs do not significantly affect the quality of life and prognosis of patients with HFpEF and can be prescribed to such patients only as part of planned therapy for the treatment of other concomitant cardiovascular diseases. |
| format | Article |
| id | doaj-art-e7bfdf4da2564104b80707cbd960393b |
| institution | Kabale University |
| issn | 2218-7332 2658-3348 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) |
| record_format | Article |
| series | Сеченовский вестник |
| spelling | doaj-art-e7bfdf4da2564104b80707cbd960393b2025-08-20T03:37:12ZrusFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Сеченовский вестник2218-73322658-33482022-10-0113341310.47093/2218-7332.2022.13.3.4-13552Chronic heart failure with preserved ejection fraction: optimal therapy. Literature reviewA. A. Kuzmenko0A. A. Sokolova1D. A. Napalkov2Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)Sechenov First Moscow State Medical University (Sechenov University)The literature review discusses approaches to the treatment of patients with chronic heart failure and preserved ejection fraction (EF>50) – HFpEF. The impact of various groups of drugs on the prognosis and quality of life of patients in this cohort was assessed based on the results of randomized trials, systematic reviews and meta-analyses, clinical recommendations of recent years. To date, only sodium-glucose cotransporter-2 inhibitors unequivocally improve the quality of life and prognosis of patients with HFpEF. Angiotensin receptor – neprilysin inhibitors and mineralocorticoid receptor antagonists are effective in terms of prognosis and quality of life only in patients with HFpEF in combination with resistant hypertension. In patients with sinus rhythm, heart rate > 70 beats/min and concomitant coronary artery disease, a combination of bisoprolol and ivabradine may be considered. Diuretics are recommended for patients with HFpEF when there are signs of congestion and signs of decompensation. Other groups of drugs do not significantly affect the quality of life and prognosis of patients with HFpEF and can be prescribed to such patients only as part of planned therapy for the treatment of other concomitant cardiovascular diseases.https://www.sechenovmedj.com/jour/article/view/870chftype 2 sodium-glucose cotransporter inhibitors (sglt2)diureticsangiotensin receptors and neprilysin inhibitor (arni)mineralocorticoid receptor antagonistssinus node if channel inhibitorbeta-blockers |
| spellingShingle | A. A. Kuzmenko A. A. Sokolova D. A. Napalkov Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review Сеченовский вестник chf type 2 sodium-glucose cotransporter inhibitors (sglt2) diuretics angiotensin receptors and neprilysin inhibitor (arni) mineralocorticoid receptor antagonists sinus node if channel inhibitor beta-blockers |
| title | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review |
| title_full | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review |
| title_fullStr | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review |
| title_full_unstemmed | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review |
| title_short | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review |
| title_sort | chronic heart failure with preserved ejection fraction optimal therapy literature review |
| topic | chf type 2 sodium-glucose cotransporter inhibitors (sglt2) diuretics angiotensin receptors and neprilysin inhibitor (arni) mineralocorticoid receptor antagonists sinus node if channel inhibitor beta-blockers |
| url | https://www.sechenovmedj.com/jour/article/view/870 |
| work_keys_str_mv | AT aakuzmenko chronicheartfailurewithpreservedejectionfractionoptimaltherapyliteraturereview AT aasokolova chronicheartfailurewithpreservedejectionfractionoptimaltherapyliteraturereview AT danapalkov chronicheartfailurewithpreservedejectionfractionoptimaltherapyliteraturereview |